Great Point Partners Llc Buys Tricida Inc, Mirati Therapeutics Inc, Zymeworks Inc, Sells Global Blood Therapeutics Inc, Biocryst Pharmaceuticals Inc, United Therapeutics Corp

• New Purchases: TCDA, MRTX, RTRX, PRTA, BHVN,
• Added Positions: ZYME, ZGNX, XLRN, BOLD, ASND, KURA, PTCT, DERM, MNTA,
• Reduced Positions: FPRX, ACAD, IOVA, MNLO, ZFGN, FOMX, OSMT,
• Sold Out: GBT, BCRX, UTHR, ARRY, PBYI, EPZM, KRYS, CBAY, CTMX, SVRA, AKBA,

For the details of GREAT POINT PARTNERS LLC's stock buys and sells, go to https://www.gurufocus.com/guru/great+point+partners+llc/current-portfolio/portfolio

1. Iovance Biotherapeutics Inc (IOVA) - 5,260,803 shares, 14.54% of the total portfolio. Shares reduced by 5.51%
2. PTC Therapeutics Inc (PTCT) - 1,974,385 shares, 10.02% of the total portfolio. Shares added by 8.83%
3. Zogenix Inc (ZGNX) - 1,593,396 shares, 8.58% of the total portfolio. Shares added by 32.83%
4. Audentes Therapeutics Inc (BOLD) - 1,922,937 shares, 8.21% of the total portfolio. Shares added by 22.28%
5. Kura Oncology Inc (KURA) - 3,047,800 shares, 6.76% of the total portfolio. Shares added by 15.22%

Great Point Partners Llc initiated holding in Tricida Inc. The purchase prices were between $31.16 and $39.46, with an estimated average price of $35.14. The stock is now traded at around $34.24. The impact to a portfolio due to this purchase was 6.33%. The holding were 1,423,998 shares as of .

Great Point Partners Llc initiated holding in Mirati Therapeutics Inc. The purchase prices were between $59.49 and $104.71, with an estimated average price of $77.61. The stock is now traded at around $88.53. The impact to a portfolio due to this purchase was 3.48%. The holding were 300,000 shares as of .

Great Point Partners Llc initiated holding in Retrophin Inc. The purchase prices were between $17.87 and $23.2, with an estimated average price of $19.73. The stock is now traded at around $17.09. The impact to a portfolio due to this purchase was 2.27%. The holding were 1,003,600 shares as of .

Great Point Partners Llc initiated holding in Prothena Corp PLC. The purchase prices were between $8.85 and $12.49, with an estimated average price of $10.27. The stock is now traded at around $7.69. The impact to a portfolio due to this purchase was 2%. The holding were 1,676,250 shares as of .

Great Point Partners Llc initiated holding in Biohaven Pharmaceutical Holding Co Ltd. The purchase prices were between $39.79 and $67.01, with an estimated average price of $56.51. The stock is now traded at around $37.38. The impact to a portfolio due to this purchase was 1.73%. The holding were 350,000 shares as of .

Great Point Partners Llc added to a holding in Zymeworks Inc by 7182.96%. The purchase prices were between $15 and $22.49, with an estimated average price of $18.31. The stock is now traded at around $26.15. The impact to a portfolio due to this purchase was 2.6%. The holding were 1,064,041 shares as of .

Great Point Partners Llc added to a holding in Zogenix Inc by 32.83%. The purchase prices were between $36.17 and $54.96, with an estimated average price of $40.18. The stock is now traded at around $50.49. The impact to a portfolio due to this purchase was 2.12%. The holding were 1,593,396 shares as of .

Great Point Partners Llc added to a holding in Acceleron Pharma Inc by 34.18%. The purchase prices were between $37.52 and $46.93, with an estimated average price of $41.39. The stock is now traded at around $45.76. The impact to a portfolio due to this purchase was 1.71%. The holding were 1,449,300 shares as of .

Great Point Partners Llc added to a holding in Audentes Therapeutics Inc by 22.28%. The purchase prices were between $35.12 and $41, with an estimated average price of $38.42. The stock is now traded at around $33.75. The impact to a portfolio due to this purchase was 1.5%. The holding were 1,922,937 shares as of .

Great Point Partners Llc added to a holding in Ascendis Pharma A/S by 20.48%. The purchase prices were between $107.11 and $132.09, with an estimated average price of $119.62. The stock is now traded at around $115.52. The impact to a portfolio due to this purchase was 1.1%. The holding were 500,000 shares as of .

Great Point Partners Llc sold out a holding in Global Blood Therapeutics Inc. The sale prices were between $52.6 and $63.29, with an estimated average price of $57.46.

Great Point Partners Llc sold out a holding in Biocryst Pharmaceuticals Inc. The sale prices were between $2.91 and $9.15, with an estimated average price of $6.01.

Great Point Partners Llc sold out a holding in United Therapeutics Corp. The sale prices were between $76.06 and $120.81, with an estimated average price of $93.52.

Great Point Partners Llc sold out a holding in Array BioPharma Inc. The sale prices were between $20.84 and $46.58, with an estimated average price of $27.97.

Great Point Partners Llc sold out a holding in Puma Biotechnology Inc. The sale prices were between $12.3 and $35.76, with an estimated average price of $23.06.

Great Point Partners Llc sold out a holding in Epizyme Inc. The sale prices were between $11.43 and $15.12, with an estimated average price of $12.87.